Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
Home > Retina > Aflibercept 8 mg and faricimab show comparable outcomes during loading phase in neovascular AMD

Aflibercept 8 mg and faricimab show comparable outcomes during loading phase in neovascular AMD

Ophthalmology 360

Key Takeaways

  1. Both aflibercept 8 mg and faricimab significantly improved visual acuity after 3 monthly injections.
  2. Central retinal thickness decreased substantially in both treatment groups.
  3. No significant differences were observed between the 2 agents in visual, anatomic, or fluid resolution outcomes.

Aflibercept 8 mg and faricimab produce significant and comparable improvements in vision and retinal anatomy after 3 loading injections in treatment-naïve neovascular age-related macular degeneration (AMD), according to a study.

The study evaluated 100 eyes from 100 patients who received 3 consecutive monthly loading injections of either aflibercept 8 mg (n = 51) or faricimab (n = 49).

In the aflibercept 8 mg group, mean best-corrected visual acuity (BCVA) improved from 0.59±0.51 logMAR (Snellen equivalent 20/77) at baseline to 0.39±0.44 (20/49) at 3 months (P < 0.001). Mean central retinal thickness (CRT) decreased from 450.6±157.0 µm to 287.3±82.3 µm (P < 0.001).

In the faricimab group, mean BCVA improved from 0.62±0.47 logMAR (20/83) to 0.45±0.38 (20/56) at 3 months (P < 0.001). Mean CRT declined from 442.4±163.8 µm to 248.5±81.2 µm (P < 0.001).

Between-group comparisons showed no significant differences in BCVA improvement (P = 0.685) or CRT reduction (P = 0.320). Complete resolution of retinal fluid occurred in 80.4% of patients treated with aflibercept 8 mg and 87.8% of those treated with faricimab, with no statistically significant difference between groups (P = 0.234).

Reference
Han HY, Park SM, Kim CG, et al. Comparison of Initial Loading Injection Outcomes Between Aflibercept 8 mg and Faricimab in Neovascular Age-Related Macular Degeneration. Retina. 2026;doi: 10.1097/IAE.0000000000004819. Epub ahead of print. PMID: 41759077.

Related Content